A Study to Learn About ABRYSVO Vaccine in Older Adults to Prevent Severe Respiratory Syncytial Virus (RSV) Disease
← catalyst calendarNCT06077968 · readout in 986 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →. With Kaiser Permanente.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-01 | actual | When the study began enrolling |
| Primary completion | 2029-05-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-05-01 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Respiratory Syncytial Viruses
Intervention
- Biological: Prior standard of care receipt of Pfizer's ABRYSVO vaccine
Primary outcomes
what the primary-completion date above is the date OF1. Vaccine Effectiveness (VE) calculated as 1 minus the odds ratio (OR) comparing the odds of being vaccinated with ABRYSVO for RSV-related hospitalized LRTD cases and controls, multiplied by 100%.
measured Up to 2 years
SSA Primary: To estimate the effectiveness of ABRYSVO® against RSV-related LRTD hospitalizations during the 3rd RSV season after a single dose
measured Up to 3 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed